INDEMNIFICATION AGREEMENT INDEMNIFICATION AGREEMENTIndemnification Agreement • October 16th, 2018 • Inhibikase Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of [●], 2018 between Inhibikase Therapeutics, Inc., a Delaware corporation (the “Company”), and [●] (“Indemnitee”).
LICENSE AGREEMENT by and between EMORY UNIVERSITY and INHIBIKASE THERAPEUTICS, INC.License Agreement • October 16th, 2018 • Inhibikase Therapeutics, Inc. • Biological products, (no disgnostic substances) • Georgia
THIS LICENSE AGREEMENT is made and entered into as of the 8th day of June 2010 (hereinafter referred to as the “Effective Date”) by and between EMORY UNIVERSITY, a nonprofit Georgia corporation with offices located at 1599 Clifton Road NE, 4th Floor, Mailstop 1599/001/1AZ Atlanta, Georgia 30322 (hereinafter referred to as "EMORY") and INHIBIKASE THERAPEUTICS, INC., a Delaware corporation having a principal place of business located at 3375 Spring Hill Parkway, Suite 811, Smyrna, GA (hereinafter referred to as "COMPANY"). EMORY and COMPANY shall be hereinafter referred to singularly as “Party” and together as “Parties."
Inhibikase Therapeutics Collaboration AGREEMENT With Parkinson’s InstituteInhibikase Therapeutics Collaboration Agreement • October 16th, 2018 • Inhibikase Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Company Sponsored Research Agreement (this “Agreement”), effective as of the date of the latest signature appearing on the signature page below (“Effective Date”), is by and between Parkinson’s Institute, with a principal place of business at 675 Almanor Avenue, Sunnyvale CA 94085 (“Institute”), and Inhibikase Therapeutics, Inc., with principal offices located at 3350 Riverwood Pkwy SE, Ste 1900, Atlanta, Georgia, 30339 (“Company”), and is subject to the terms and conditions set forth herein.
LICENSE AGREEMENTLicense Agreement • October 16th, 2018 • Inhibikase Therapeutics, Inc. • Biological products, (no disgnostic substances)
THIS LICENSE AGREEMENT is entered into this 18th day of June 2010 (the “Effective Date”) by and between DUKE UNIVERSITY ("DUKE"), a nonprofit educational and research institution organized under the laws of North Carolina, having a place of business at Durham, North Carolina 27710, and INHIBIKASE THERAPEUTICS, INC. ("Licensee"), a corporation organized under the laws of Delaware, with its corporate headquarters at 3375 Spring Hill Parkway, Suite 811, Smyrna, GA 30080. DUKE and Licensee shall hereinafter be referred to in the singular as a “Party” and collectively and the “Parties.”
INHIBIKASE THERAPEUTICS FIRST AMENDMENT TO COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTAnd Development Agreement • October 16th, 2018 • Inhibikase Therapeutics, Inc. • Biological products, (no disgnostic substances)
THIS FIRST AMENDMENT TO THE COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (“Agreement”) is entered into with an effective date as of the 5th day of October 2012 (the “Amendment Effective Date”) by and among, on the one hand, Inhibikase Therapeutics, Inc., a Delaware corporation, with offices located at 3350 Riverwood Parkway, Suite 1927, Atlanta, Georgia (the “Company”) and, on the other hand, Sphaera Pharma Pte. Ltd., a company incorporated under the laws of Singapore with its registered office at 8 Temasek Boulevard, #22-03 Suntec Tower 3, Singapore 038988 (“Sphaera Singapore”) and Sphaera Pharma Pvt. Ltd., with its registered office at E-375, First Floor, Greater Kailash-II, New Delhi-110048, INDIA (“Sphaera India”)(together with Sphaera Singapore, hereinafter referred to as “Sphaera Pharma”). (Company and Sphaera Pharma shall be referred to individually as a “Party” and collectively as the “Parties.”) Except as otherwise provided in this Agreement, capitalized terms and phrases
INIHIBIKASE THERAPEUTICS COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTCollaborative Research and Development Agreement • October 16th, 2018 • Inhibikase Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
THIS COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (“Agreement”) is entered into with an effective date as of the 29th day of February 2012, by and among, on the one hand, Inhibikase Therapeutics, Inc., a Delaware corporation, with offices located at 3350 Riverwood Parkway, Suite 1927, Atlanta, Georgia (the “Company”) and, on the other hand, Sphaera Pharma Pte. Ltd., a company incorporated under the laws of Singapore with its registered office at 8 Temasek Boulevard, #22-03 Suntec Tower 3, Singapore 038988 (“Sphaera Singapore”) and Sphaera Pharma Pvt. Ltd., Plot No. 32, Sector 5, IMT Manesar Haryana 122051, India (“Sphaera India”)(together with Sphaera Singapore, hereinafter referred to as “Sphaera Pharma”). (Company and Sphaera Pharma shall be referred to individually as a “Party” and collectively as the “Parties.”)
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • October 16th, 2018 • Inhibikase Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) dated as of [·], 2017, by and among Inhibikase Therapeutics, Inc., a Delaware corporation (the “Company”) and [MW] (the “Stockholder”). Capitalized terms used but not otherwise defined herein shall have the meaning ascribed to such terms in Section 1.
